Generic Name: belantamab mafodotin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: GlaxoSmithKline

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

General Info

Blenrep consists of an antibody that targets the B-cell maturation antigen (BCMA), found on plasma cells that grow out of control in multiple myeloma, and a chemotherapy drug that inhibits cell division and causes apoptosis (cell suicide).

In the DREAMM-2 trial, the overall response rate for people treated with the optimal dose of Blenrep was 31%, and nearly three quarters of responders had a response duration of at least six months. Blenrep was first approved in August 2020.


Dosing Info:

Blenrep is administered by intravenous infusion every three weeks.

Side Effects

Common adverse reactions include changes to the cornea of the eye, decreased visual acuity, blurred vision, nausea, fever, fatigue and infusion reactions. Blenrep can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects include corneal ulcers and vision loss. Blenrep can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 9, 2020